Chronic kidney disease and the heart-kidney-metabolic overlap: SGLT2 inhibitors, GLP-1 RAs, lipids, diabetes and cardiovascular risk.
Weekly
Two ways to clear more middle molecules arrive in US dialysis units at once. A urine dipstick can show whether patients are taking their SGLT2 inhibitor. Two papers disagree about who should let AI write the notes. Nine picks from the week of September 21, 2026, each with the story, the numbers…
CKD and cardiometabolic
The authors argue nephrology must move upstream into cardio-kidney-metabolic care, and that the AHA's CKM model undersells the kidney. If nephrologists stay out, CKD will be found more often but diagnosed less precisely.
CKD and cardiometabolic
A CJASN review explains why atherosclerosis runs hot in CKD, why chest pain and standard risk scores mislead, which treatments have evidence, plus an inflammation trial that missed.
CKD and cardiometabolic
A CJASN How I Treat case argues the barrier to GLP-1 receptor agonists in CKD is putting them into practice, not the evidence. It lays out titration, lab checks, insulin cuts and how to protect muscle.
CKD and cardiometabolic
In 45,711 patients newly prescribed an SGLT2 inhibitor, glucose on a routine dipstick went with lower mortality, heart failure hospitalization and kidney failure, while fractures didn't budge. The study is observational, but the check is free.